Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.

Fucun Xie,Bowen Chen,Xu Yang,Huaiyuan Wang, Ge Zhang,Yanyu Wang,Yunchao Wang,Nan Zhang,Jingnan Xue,Junyu Long,Yiran Li,Huishan Sun,Ziyu Xun,Kai Liu,Xiangqi Chen,Yang Song,Xiaobo Yang,Zhenhui Lu,Yilei Mao,Xinting Sang,Yinying Lu,Haitao Zhao

Frontiers in immunology（2022）

Cited 0|Views12
No score
Abstract
ICI plus MTA in aHCC patients after the progression of lenvatinib presented high antitumor activity and safety. Patients could continue lenvatinib treatment and receive ICIs as well as locoregional treatment to achieve better OS.
More
Translated text
Key words
efficacy,hepatocellular carcinoma (HCC),immune checkpoint inhibitor (ICI),lenvatinib,molecular targeted agent (MTA),safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined